Novo Nordisk stock jumped early Wednesday after the weight-loss drugs leader reported adjusted earnings of 88 cents per share ...

Popular drugs like Ozemic and Monjauro aid in managing diabetes by lowering blood sugar levels. They have surged in popularity because they hasten weight loss. And this new class of drugs —GLP-1 ...

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely ...

A gold-standard University College of London study found a type of weight-loss jab had no benefit in alleviating a condition ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...

A Nova radio host has admitted live on-air to taking a weight loss drug popular with celebrities that costs an arm and a leg ...

Ozempic, which accounts for 41% of the company's sales, is an injectable anti-diabetic treatment that became wildly popular ...

Follow the latest news headlines from Australia's most trusted source. Read in-depth expert analysis and watch live coverage ...

Experts are calling on the government to implement strategies that will better predict future Ozempic shortages.